Meet Ron Kilgarlin, Founder of American Screening Corp, at PBSA 2025. Uncover his journey from startup to screening innovator!
Ron Kilgarlin’s journey is a testament to the power of resilience and purpose. For a time, it seemed life had derailed beyond repair. Yet from those depths, Ron resolved to rewrite his story. “I’ve walked through fire, fallen to ashes, and still — I rise, like a phoenix,” he proclaims.
Introduction
The healthcare industry is standing at a pivotal crossroads — grappling with issues of rising costs, access disparities, outdated infrastructure, and the ever-growing demand for speed, accuracy, and personalization in diagnostics. While policymakers, providers, and innovators continue to explore solutions, few voices are as uniquely positioned in this landscape as Ron Kilgarlin, CEO of American Screening Corporation (ASC) and founder of RevealBackground.com.
With decades of experience in medical diagnostics, compliance, and employment screening, Ron brings a deep, hands-on understanding of what’s broken in the system — and more importantly, what can be fixed. In this candid conversation, Ron offers an unfiltered perspective on the biggest challenges healthcare faces today, what solutions are on the horizon, and how companies like AmericanScreeningCorp.com and RevealBackground.com are actively reshaping the future.
Healthcare in 2025: A Broken System or a Reinvention Opportunity?
According to Ron, the biggest issue in healthcare is not a lack of resources, but a lack of alignment.
“We have incredible technology, brilliant people, and groundbreaking therapies — but we’re not connecting the dots fast enough. Diagnostics, patient access, and compliance still operate in silos,” Ron explains. “That fragmentation leads to delays, miscommunication, and, ultimately, patient harm.”
He points to the supply chain shocks during the COVID-19 pandemic as a turning point. “What we learned during the pandemic is that speed, flexibility, and data are the real currency in healthcare — not just medication and machines.”
This insight became the foundation for how ASC and Reveal have evolved post-2020.
ASC’s Mission: Empowering Diagnosis and Prevention
American Screening Corporation, accessible online at AmericanScreeningCorp.com, was built on the belief that accurate, fast, and affordable diagnostics are the gateway to better healthcare outcomes.
Founded in Louisiana in 2004, ASC started with a handful of drug testing kits and has grown into a globally recognized manufacturer and distributor of medical testing devices, serving major healthcare providers, employers, government agencies, law enforcement, and educational institutions.
What Sets ASC Apart?
FDA & CLIA-Waived Products: ASC offers hundreds of test kits that are FDA-cleared and CLIA-waived, making them suitable for point-of-care use in both clinical and non-clinical settings.
Rapid Turnaround: Whether it’s a 12-panel urine drug test, a fentanyl strip, or a genetic swab, ASC ships most orders same-day, including bulk orders for high-volume clients.
Domestic Manufacturing: ASC manufactures most of its products in-house, ensuring quality control, supply chain stability, and compliance with U.S. regulations.
Custom Branding and Private Labeling: Clinics, treatment centers, and labs can customize test kits under their own brand, helping them streamline operations and build trust with patient
One of the most significant trends in biotech today is the movement toward precision medicine — healthcare tailored to the individual. This approach utilizes genetic, environmental, and lifestyle data to develop more accurate diagnoses, treatments, and preventive strategies. According to Kilgarlin, precision medicine is revolutionizing the diagnostic testing industry, including drug testing, by enabling more targeted and effective interventions.
“Precision medicine allows us to move away from a one-size-fits-all approach,” says Ron Kilgarlin. “In drug testing and diagnostics, it means creating tools that consider the unique biological makeup of the individual, which leads to more accurate results and better outcomes.”
Biotech companies are now investing heavily in the development of personalized therapies, from targeted cancer treatments to pharmacogenomics that determine how patients will respond to specific medications. This shift is not only improving patient outcomes but also reducing healthcare costs by minimizing trial-and-error treatment strategies.
Substance abuse refers to the harmful or hazardous use of psychoactive substances, including alcohol, illicit drugs, and prescription medications. It often begins with occasional use or experimentation and can escalate to dependence and addiction, impacting physical and mental health. Substance abuse disrupts brain chemistry, impairing decision-making, memory, and self-control, which makes quitting without support challenging. Beyond the individual, substance abuse affects families, workplaces, and communities, contributing to strained relationships, reduced productivity, and increased healthcare costs.